| 5.64 0.27 (5.03%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.4 |
1-year : | 8.65 |
| Resists | First : | 6.34 |
Second : | 7.4 |
| Pivot price | 5.54 |
|||
| Supports | First : | 5.32 |
Second : | 4.69 |
| MAs | MA(5) : | 5.35 |
MA(20) : | 5.47 |
| MA(100) : | 4.59 |
MA(250) : | 5.61  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 34.1 |
D(3) : | 28.1 |
| RSI | RSI(14): 56.9 |
|||
| 52-week | High : | 11.19 | Low : | 1.03 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SGHT ] has closed below upper band by 42.2%. Bollinger Bands are 20.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.88 - 5.9 | 5.9 - 5.92 |
| Low: | 5.18 - 5.21 | 5.21 - 5.23 |
| Close: | 5.6 - 5.63 | 5.63 - 5.68 |
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Mon, 22 Apr 2024
With 34% ownership, Sight Sciences, Inc. (NASDAQ:SGHT) has piqued the interest of institutional investors - Yahoo Finance
Fri, 19 Apr 2024
Wall Street Analysts See a 200% Upside in Sight Sciences, Inc. (SGHT): Can the Stock Really Move This High? - Yahoo Movies UK
Thu, 18 Apr 2024
Sight Sciences to Report First Quarter Financial Results on May 2, 2024 - GlobeNewswire
Wed, 10 Apr 2024
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive ... - GlobeNewswire
Tue, 26 Mar 2024
SGHT Stock Quote Price and Forecast - CNN
Thu, 07 Mar 2024
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 50 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 21.7 (%) |
| Held by Institutions | 51.4 (%) |
| Shares Short | 1,290 (K) |
| Shares Short P.Month | 1,390 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.45 |
| Profit Margin | -68.6 % |
| Operating Margin | -59.3 % |
| Return on Assets (ttm) | -18.9 % |
| Return on Equity (ttm) | -39.7 % |
| Qtrly Rev. Growth | -8.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | -1.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -4.95 |
| PEG Ratio | 0 |
| Price to Book value | 2.3 |
| Price to Sales | 3.44 |
| Price to Cash Flow | -5.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|